Replimune Group, Inc. pioneers the development of oncolytic immunotherapies designed to synergize with existing cancer treatments, including immune checkpoint inhibitors. The company's core technology, the RPx platform, uses a genetically modified herpes simplex virus type 1 (HSV-1) backbone to maximize immunogenic cell death and induce a durable anti-tumor immune response. Its lead product candidate, RP1 (vusolimogene oderparepvec), is being evaluated in clinical trials for advanced solid tumors, particularly melanoma that has failed prior anti-PD-1 therapies. Replimune also advances a pipeline of additional candidates, such as RP2 and RP3, which encode further immune-activating proteins. The company operates an in-house, commercial-scale manufacturing facility in Framingham, Massachusetts, to support its clinical and future commercial supply needs.
